Rabbit Anti-Human ERCC1 (a.a. 151-250) Polyclonal antibody

Name: Rabbit Anti-Human ERCC1 (a.a. 151-250) Polyclonal antibody
SKU: DPABH-17264
Rating: 5 (1 reviews)

Rabbit Anti-Human ERCC1 (a.a. 151-250) Polyclonal antibody for WB, IHC-P, IHC-F, IF

Write a review

COA

SDS

Datasheet

Key features and details

Target: ERCC1
Host: Rabbit
Application: WB, IHC-P, IHC-F, IF
Species Reactivity: Human, Mouse, Rat, Dog, Pig, Cow

Summary

Specifications

Antibody Isotype

IgG

Species Reactivity

Human; Mouse; Rat; Dog; Pig; Cow

Immunogen

KLH conjugated synthetic peptide derived from human ERCC1: 151-250/297

Conjugate

Unconjugated

Applications

Application Notes

WB: 1:500-2000
IHC-P: 1:100-500
IHC-F: 1:100-500
IF: 1:100-500

General Notes

This product (Catalog No. DPABH-17264) is a rabbit-derived IgG polyclonal antibody raised against human ERCC1, targeting the amino acid region 151–250 of the protein. This antibody exhibits cross-reactivity with ERCC1 from mouse, rat, dog, pig, and cow. It has been affinity purified by Protein A. The product of this gene functions in the nucleotide excision repair pathway, and is required for the repair of DNA lesions such as those induced by UV light or formed by electrophilic compounds including cisplatin. The encoded protein forms a heterodimer with the XPF endonuclease (also known as ERCC4), and the heterodimeric endonuclease catalyzes the 5' incision in the process of excising the DNA lesion. The heterodimeric endonuclease is also involved in recombinational DNA repair and in the repair of inter-strand crosslinks. Mutations in this gene result in cerebrooculofacioskeletal syndrome, and polymorphisms that alter expression of this gene may play a role in carcinogenesis. Multiple transcript variants encoding different isoforms have been found for this gene. The last exon of this gene overlaps with the CD3e molecule, epsilon associated protein gene on the opposite strand.
DPABH-17264 is suitable for use in Western blot (WB) (1:500–1:2,000), IHC-P (1:100–1:500), IHC-F (1:100–1:500), IF (immunofluorescence) (1:100–1:500) applications.
DPABH-17264 is supplied as a liquid formulation in 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. For long-term storage, keep at −20 °C. For short-term use, store at 2–8 °C. Avoid repeated freeze–thaw cycles to maintain antibody integrity and performance.

Target

Alternative Names

Excision Repair Cross Complementing 1; DNA excision repair protein ERCC-1; COFS4; UV20; DNA excision repair protein ERCC1; ERCC 1; Excision Repair Cross Complementing Rodent Repair Deficiency Complementation Group 1; Excision repair protein; UV 20; UV20; DNA excision repair protein ERCC-1

Entrez Gene ID

2067

UniProt ID

P07992

Citations

Have you cited DPABH-17264 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

A Review of Molecular Predictors of Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer

MINI-REVIEWS IN MEDICINAL CHEMISTRY

Authors: Degener, Stephan; Mata, Douglas A.; Youssef, Ramy; Goedde, Daniel; Tandogdu, Zafer; Roth, Stephan; von Rundstedt, Friedrich-Carl

Abstract

Locally advanced, muscle-invasive urothelial carcinoma of the bladder (MIBC) may be definitively treated with either radiotherapy or radical cystectomy (RC) with urinary diversion. Neoadjuvant chemotherapy (NAC) is typically administered prior to treatment with either modality. Receiving NAC prior to RC might confer a survival advantage compared to undergoing RC alone. However, its usefulness has been questioned due to concerns about over treatment and toxicity. Having the ability to predict whether individual patients would benefit from or be harmed by NAC would be an important tool in precision medicine. Unfortunately, to date no prognostic or predictive molecular markers have been validated for this purpose. In this manuscript, we review the current state of molecular markers in MIBC treatment and outline how recent advances in whole-genome sequencing may soon improve the selection of precisely targeted therapeutics for the benefit of individual patients.

Computer-aided drug design of small molecule inhibitors of the ERCC1-XPF protein-protein interaction

CHEMICAL BIOLOGY & DRUG DESIGN

Authors: Gentile, Francesco; Elmenoufy, Ahmed H.; Ciniero, Gloria; Jay, David; Karimi-Busheri, Feridoun; Barakat, Khaled H.; Weinfeld, Michael; West, Frederick G.; Tuszynski, Jack A.

Abstract

The heterodimer of DNA excision repair protein ERCC-1 and DNA repair endonuclease XPF (ERCC1-XPF) is a 5 '-3 ' structure-specific endonuclease essential for the nucleotide excision repair (NER) pathway, and it is also involved in other DNA repair pathways. In cancer cells, ERCC1-XPF plays a central role in repairing DNA damage induced by chemotherapeutics including platinum-based and cross-linking agents; thus, its inhibition is a promising strategy to enhance the effect of these therapies. In this study, we rationally modified the structure of F06, a small molecule inhibitor of the ERCC1-XPF interaction (Molecular Pharmacology, 84, 2013 and 12), to improve its binding to the target. We followed a multi-step computational approach to investigate potential modification sites of F06, rationally design and rank a library of analogues, and identify candidates for chemical synthesis and in vitro testing. Our top compound, B5, showed an improved half-maximum inhibitory concentration (IC50) value of 0.49 mu M for the inhibition of ERCC1-XPF endonuclease activit, and lays the foundation for further testing and optimization. Also, the computational approach reported here can be used to develop DNA repair inhibitors targeting the ERCC1-XPF complex.